Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,571,985

-0.14 (-0.62%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $22.25 -0.15 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Universal Health (UHS) Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Universal Health Services, Inc. (UHS) will release fourth-quarter 2016 results on Feb 28, after the market closes. Last quarter, the company posted a negative earnings surprise of 4.19%.

    Zacks Equity Research

    Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.

      Zacks Equity Research

      Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?

      by Zacks Equity Research

      Arena Pharmaceuticals, Inc. (ARNA) is expected to report fourth-quarter 2016 results next month.

        Zacks Equity Research

        Keryx (KERX) Q4 Earnings: What's in Store for the Stock?

        by Zacks Equity Research

        Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.

          Zacks Equity Research

          Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?

          by Zacks Equity Research

          Tenet Healthcare Corporation (THC) will release fourth-quarter 2016 results on Feb 27, after the market closes. Let's see how things are shaping up for this announcement.

            Zacks Equity Research

            Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?

            by Zacks Equity Research

            Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter

              Zacks Equity Research

              Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?

              by Zacks Equity Research

              Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.

                Zacks Equity Research

                ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?

                by Zacks Equity Research

                ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.

                  Zacks Equity Research

                  Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?

                  by Zacks Equity Research

                  Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.

                    Zacks Equity Research

                    Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?

                    by Zacks Equity Research

                    Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.

                      Zacks Equity Research

                      Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?

                      by Zacks Equity Research

                      Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.

                        Zacks Equity Research

                        Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

                        by Zacks Equity Research

                        Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                          Zacks Equity Research

                          Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?

                          by Zacks Equity Research

                          Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.

                            Zacks Equity Research

                            Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?

                            by Zacks Equity Research

                            Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.

                              Zacks Equity Research

                              Geron (GERN) Q4 Earnings: What's in Store for the Stock?

                              by Zacks Equity Research

                              Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

                                Zacks Equity Research

                                Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

                                by Zacks Equity Research

                                Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

                                  Zacks Equity Research

                                  Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options

                                  by Zacks Equity Research

                                  Pacira Pharmaceuticals (PCRX) warrants investors' attention based on moves in the options market lately.

                                    Zacks Equity Research

                                    What's in Store for ImmunoGen (IMGN) this Earnings Season?

                                    by Zacks Equity Research

                                    ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

                                      Zacks Equity Research

                                      Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?

                                      by Zacks Equity Research

                                      Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.